Agenus traded at $2.98 this Wednesday February 11th, decreasing $0.09 or 2.93 percent since the previous trading session. Looking back, over the last four weeks, Agenus lost 29.88 percent. Over the last 12 months, its price fell by 13.87 percent. Looking ahead, we forecast Agenus to be priced at 0.47 by the end of this quarter and at 0.43 in one year, according to Trading Economics global macro models projections and analysts expectations.
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.